HIV Drug Development

Update item information
Identifier HIV_drug_development
Title HIV Drug Development
Creator Sundquist, W.I., Kay, M.S., Hill, C.P.; Biochemistry; School of Medicine; University of Utah Health
Subject Diffusion of Innovation; HIV-1; Virus Internalization; Drug Development; Anti-HIV Agents; Vaccines; HIV Infections; HIV Envelope Protein gp41; Molecular Sequence Data; Sequence Alignment; Peptides; Peptie Library; Drug Delivery Systems; Immunotherapy, Active; Clinical Trial, Phase I; Knowledge Discovery
Keyword Drug Discovery
Image Caption Structure showing different elements of a D-peptide inhibitor (PIE12, yellow) binding to its HIV target.
Description Our NIH P50 CHEETAH Center supports basic research in HIV structural biology and molecular virology, with the long-term goal of identifying effective new strategies for therapies, vaccines, and cures. Fundamental studies of HIV capsid structure and function performed by Sundquist, Hill, and colleagues formed the basis for Gilead's development of highly potent, and remarkably long-lasting HIV capsid inhibitors that support quarterly dosing. These inhibitors have now entered Phase II clinical trials. Similarly, pioneering studies of D-peptide inhibitors by Kay and colleagues produced a highly potent inhibitor of HIV entry that will enter Phase I trials in 2020.
Relation is Part of 2019
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2020
Date 2019
Type Image
Format image/jpeg
Rights Management Copyright © 2021, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s6ms9gvf
References 1.) Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery. Redman JS, Francis JN, Marquardt R, Papac D, Mueller AL, Eckert DM, Welch BD, Kay MS. Molecular Pharmacology. 2018 Mar;15(3):1169. https://pubmed.ncbi.nlm.nih.gov/29436835/ 2.) A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, Stepan GJ, Jin D, Wong MH, Perreira JM, Singer E, Papalia GA, Hu EY, Zheng J, Lu B, Schroeder SD, Chou K, Ahmadyar S, Liclican A, Yu H, Novikov N, Paoli E, Gonik D, Ram RR, Hung M, McDougall WM, Brass AL, Sundquist WI, Cihlar T, Link JO. Nature Medicine. 2019 Sep;25(9):1377. https://pubmed.ncbi.nlm.nih.gov/31501601/
Press Releases and Media POZ Newsletter https://www.poz.com/article/gileads-hiv-capsid-inhibitor-worked-1st-human-trial; Fierce Biotech https://www.fiercebiotech.com/biotech/gilead-s-long-acting-hiv-med-cuts-viral-load-phase-1b; Bloomberg Business https://www.bloomberg.com/press-releases/2019-07-22/gilead-presents-proof-of-concept-data-for-gs-6207-a-first-in-class-capsid-inhibitor-in-people-living-with-hiv
Setname ehsl_50disc
Date Created 2020-08-13
Date Modified 2021-05-06
ID 1589350
Reference URL https://collections.lib.utah.edu/ark:/87278/s6ms9gvf
Back to Search Results